MRS-1845 is primarily utilized in research settings as a selective antagonist for the P2X7 receptor, which plays a significant role in immune responses and inflammation. Its application is crucial in studying the mechanisms of inflammatory diseases, such as arthritis and neurodegenerative disorders, as it helps in understanding the receptor's function in immune cell activation and cytokine release. Additionally, MRS-1845 is employed in pharmacological studies to explore potential therapeutic interventions for conditions involving excessive inflammation or immune dysregulation. Its ability to block P2X7 receptor activity makes it a valuable tool in developing treatments for chronic pain, autoimmune diseases, and other inflammation-related pathologies.